Interview with the Innovators

The Impact of New Driver Mutations on Treatment of NSCLC

Interview with the Innovators
Best Practices in Lung Cancer Navigation
Video Library

Featuring:

Lauren Welch, MSN, NP-C, AOCNP
Nurse Practitioner
Tennessee Oncology
Nashville, TN
Lauren Welch, MSN, NP-C, AOCNP, discusses the impact that the discovery of new actionable molecular targets and oncogenic drivers has had on treatment of NSCLC, with at least 6 new targets, all with approved targeted therapies. She suggests that patients have better outcomes with targeted therapies upfront, so that identification of these targets early through broad NGS testing is essential in extending survival in patients with NSCLC.

Related Items

Assessing Patient Risk Before ADC Therapy in Breast Cancer
By Tajuana Bradley, MS, FNP-BC; Abbey J. Kaler, MS, APRN, FNP-C
Interview with the Innovators
Video Library
How can early identification of patient-specific risk factors help optimize patient outcomes and proactively manage toxicity with ADC therapy? In this video, Tajuana Bradley, DNP, FNP-BC, AOCNP, and Abbey Kaler, PA-C, discuss approaches to evaluating baseline risk factors, identifying patients who may be at increased risk for key ADC-related toxicities, and implementing monitoring, multidisciplinary care, and patient education strategies at treatment initiation.
Improving Abemaciclib Tolerability: Insights From the TRADE Dose-Escalation Study
By Jamie Carroll, APRN, CNP, MSN
Interview with the Innovators
Video Library
In this sixth installment, Ms Carroll discusses the TRADE study with abemaciclib and emphasizes the importance of individualized patient care, clear communication about dosing goals, and teamwork among healthcare providers to implement dose escalation effectively. This strategy aims to address patient concerns about side effects while ensuring adherence to the full treatment plan.
Managing Abemaciclib Side Effects: Practical Tips for Improving Patient Care
By Jamie Carroll, APRN, CNP, MSN
Interview with the Innovators
Video Library
In this fifth installment, Ms Carroll discusses strategies for managing adverse events associated with abemaciclib, emphasizing the importance of patient involvement and personalized care. She underscores the value of maintaining open communication and regular touchpoints with patients to address concerns, build trust, and ensure adherence to therapy. These strategies aim to improve the quality of life for patients on abemaciclib.
Journal of Oncology Navigation & Survivorship

Contact Us | Editorial Board

Amplity

© Amplity, Inc. All rights reserved.

Connect with Us

 
 
JONS

Subscribe Today!

To sign up for our print publication or e-newsletter, please enter your contact information below.

I'd like to receive:

  • First Name *
    Last Name *
     
    Profession or Role
    Primary Specialty or Disease State
    Country

Back to Top

Amplity © Amplity, Inc. All rights reserved.